Journal
CELL BIOCHEMISTRY AND FUNCTION
Volume 34, Issue 7, Pages 511-515Publisher
WILEY
DOI: 10.1002/cbf.3224
Keywords
biomarker; miR-221; Parkinson's disease; serum miRNA
Categories
Funding
- Department of Science and Technology of Shandong Province, China [2014GSF118024]
Ask authors/readers for more resources
Parkinson's disease (PD) is the common age-related neurodegenerative disorder. Sensitive, non-invasive biomarkers that facilitate PD diagnosis and stage assignment are currently unavailable. This study aims to investigate the potential of 16 previous reported PD-associated miRNAs as novel biomarkers for PD. The expression of 16 serum miRNAs was measured by quantitative reverse transcriptase polymerase chain reaction in 138 PD patients and 112 control populations. Analyses were undertaken to assess the specificity and sensitivity of miRNAs to predict PD. In addition, the relationship between deregulated miRNAs and Part III of the United Parkinson's Disease Rating Scale (UPDRS-III) and Part V of the UPDRS (UPDRS-V; the modified Hoehn and Yahr staging of PD) in PD patients was also assessed. It was found that the serums miR-29c, miR-146a, miR-214, and miR-221 were significantly decreased in PD patients compared with healthy control populations. In addition, serum miR-221 was positively correlated with UPDRS-III (r=.4702) and UPDRS-V (r=.4788) score in PD patients. Furthermore, the receiver operating characteristic result of serum miR-221 for prediction of PD was 0.787. Our preliminary findings indicate that downregulated serum miR-221 might be a potential biomarker for PD evaluation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available